According to these data, except for the increased risk of heart failure with saxagliptin, DPP-4 inhibitors should be considered safe in T2D with or at risk of PAD, but also a second choice when compared to GLP-1 RA or SGLT2i. The gene discussed is GLP1R; the disease is peripheral arterial disease.